Research grade stem cell lines
The UK Stem Cell Bank provides extensive quality control on available research-grade human stem cell lines. This includes tests to ensure the safety (sterility and mycoplasma), identity (STR profile), and potency (gene profile) of the cell lines. A Certificate of Analysis is provided with each order. The UK Stem Cell Bank also offers technical advice and cell line information to support customers in choosing the most appropriate cell line for their research.
To obtain cell lines, visit our Apply for Stem Cell Lines page.
If you have any queries, please do not hesitate to get in touch at: enquiriesmail@mhra.gov.uk.
Cell Line Information
| Deep Characterisation
| Availability |
Cell Line
|
Bank Designation
|
Feeder Status
|
UK Steering Committee Approval #
|
UK Stem Cell Bank Accession Number
|
Karyotype
|
OncoPanel Testing
|
Whole Genome Sequencing
|
Clinical Release Status
|
Research Release Status
|
Cell Line Information
|
KCL032 |
|
Feeder Free |
SCSC11-58-(d) |
C-16-012 |
46XY(30) |
Tier 4
|
✔ |
Released
|
Released |
X
|
MasterShef11 |
|
Feeder Free |
SCSC13-06 |
C-16-021 |
46XY |
Tier 4 |
✔ |
Released |
Released |
More information |
RC11 |
|
Feeder Free |
SCSC11-02 |
C-18-038 |
46XX |
Tier 4
|
✔ |
Released |
Released |
More information |
RC17 |
|
Feeder Free |
SCSC11-38 |
C-18-044 |
46XX |
Tier 4 |
✔ |
Released |
Released |
More information |
Tier 1 |
The alteration has well-established published evidence confirming clinical utility in this tumour type, in at least one of the following contexts: predicting response to treatment with an FDA-approved therapy; strongly supportive in establishing a definitive diagnosis; assessing prognosis; or conferring an inherited increased risk of cancer to this patient and family. |
Tier 2 |
The alteration may have clinical utility in at least one of the following contexts: selection of an investigational therapy in clinical trials for this cancer type; limited evidence of prognostic association; supportive of a specific diagnosis; proven association of response to treatment with an FDA-approved therapy in a different type of cancer; or similar to a different mutation with a proven association with response to treatment with an FDA-approved therapy in this type of cancer. |
Tier 3 |
The alteration is of uncertain clinical utility, but may have a role as suggested by at least one of the following: demonstration of association with response to treatment in this cancer type in preclinical studies (e.g., in vitro studies or animal models); alteration in a biochemical pathway that has other known, therapeutically-targetable alterations; alteration in a highly conserved region of the protein predicted, in silico, to alter protein function; or selection of an investigational therapy for a different cancer type. |
Tier 4 |
The alteration is novel, or its significance has not been studied in cancer. A subset of these alterations likely represents normal germline variants as the assay is not analysed in conjunction with a matched normal from the same patient. |